ESCMID Online Lecture Library. by author
|
|
- Gyles Raymond Wood
- 5 years ago
- Views:
Transcription
1 Novel PK/PD data on the optimisation of colistin and the carbapenems Diamantis Plachouras Athens, Greece Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course, 31 May - 01 June 2013, Athens
2 Overview Principles of PK/PD in ICU Carbapenems: prolonged/continuous or intermittent infusion? Colistin dosing Combination treatment Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
3 Principles of PK/PD in ICU Carbapenems: prolonged/continuous or intermittent infusion? Colistin dosing Combination treatment Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
4 Killing curves concentration dependent time dependent Craig WA. Scand J Infect Dis 1992
5 MIC PK/PD indices T>MIC AUC AUC PK/PD indices T>MIC AUC/MIC Cmax/MIC
6 Meropenem vs. Klebsiella
7 Meropenem vs. Klebsiella
8 β-lactam PK/PD target (T>MIC percentage of dosing interval) Class Organism Stasis Maximum killing Cephalosporins Gram-negative Stapholococcus Penicillins Gram-negative Stapholococcus Carbapenems Gram-negative Stapholococcus Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
9 What is special in the ICU? More severe infections More resistant bugs Altered pharmacokinetics Volume of distribution (V d ) Endothelial dysfunction Edema Hypoalbuminemia increased clearance Inotropes increased clearance Rapid alteration in physiological status Immuno-compromised host Hydrophilic antimicrobials Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens McKenzie C. J Antimicrob Chemoth 2011
10 Antibiotic dosing in critical illness Higher PK/PD targets Higher inocula e.g. VAP Continuous prolonged vs short infusions Resistance prevention Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens McKenzie A. JAC 2011
11 Principles of PK/PD in ICU Carbapenems: prolonged/continuous or intermittent infusion? Colistin dosing Combination treatment Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
12 Meropenem PK/PD Bolus Continuous Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
13 Prolonged vs 30 min infusion of meropenem Kuti JL. J Clin Pharmacol 2003 ; 43( 10) :
14 Target attainment with 30 min vs 4 h infusion Lodise TP. Clin Infect Dis 2007
15 Clinical efficacy with 30 min vs 44 h h infusion Lodise TP. Clin Infect Dis 2007 Lodise TP. Clin Infect Dis 2007
16 Target attainment with various meropenem dosage regimens Roberts JA. J. Antimicrob. Chemother. (2009) 64 (1): Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
17 In vitro pharmacodynamic simulation of 3h meropenem infusion against CPKP Bulik CC. Antimicrob. Agents Chemother 2010; 54 (2):
18 Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysis Falagas ME. Clin Infect Dis. (2013) 56 (2):
19 Characteristics and outcomes of the carbapenem studies included in the metaanalysis Author, Year Esterly, 2010 Okimoto, 2009 Wang, 2009 Sakka, 2007 Itabashi, 2007 Lorente, 2006 Dow, 2011 Study Design; Years, Country Retrospective; NR, USA Prospective; NR, Japan Retrospective; 2006, China RCT; NR, Germany Prospective; , Japan Retrospective; , Spain Retrospective; , USA No. of Patients ; Infections Bacteria Dosage Regimen (IV) 71; bacteremia A. baumannii, P. aerug, ESBL (+) Enterobacteriaceae IMI/CIL or MER 3-h in vs IMI/CIL or MER 30- min in 50; CAP in Gram ( ): 15 MER 1 g continuously the elderly Gram (+): 14 vs Unknown: 21 MER 500 mg q12h 30min in 30; ICU - A. baumannii MER 500 mg q6h 3-h HAP in vs MER 1g q8h 1h 20; ICUacquired Gram ( ) IMI/CIL 2/2 g continuously pneumonia vs IMI/CIL 1/1 g q8h 40-min in 42 ; severe Gram ( ): 10 MER 500 mg q12h 4- pneumonia Gram (+): 10 h in Others, unkn.: 34 vs MER 500 mg q12h 1- h in 89 ; VAP Gram ( ) MER 1 g continuously vs MER 1 g q6h 30-min in 121 ; ICU Gram ( ) PIP/TAZ 3/0.375 g infections q8h or MER 500 mg q6h 3 or 4-h in vs PIP/TAZ 3/0.375 g q6h or MER 500 mg q6h 30-min inf Clinical Cure Mortality Extended or Short-Term Extended or Short-Term Continuous Infusion, Continuous Infusion, Infusion, n/n n/n (%) Infusion, n/n n/n (%) (%) (%) NR NR 12/42 (28.6) 7/29 (24.1) 20/25 (80) 19/25 (76) 0/25 (0) 0/25 (0) 15/15 (100) 15/15 (100) 0/15 (0) 0/15 (0) NR NR 1/10 (10) 2/10 (20) NR NR 1/18 (5.6) 9/24 (37.5) 38/42 (90.5) 28/47 (59.6) NR NR NR NR 8/67 (11.9) 11/54 (20.4) Falagas ME. Clin Infect Dis. (2013) 56 (2): Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
20 Forest plot of mortality Falagas ME. Clin Infect Dis. (2013) 56 (2): Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
21 What about stability? Meropenem less stable than doripenem More degradation with increased temperature and concentration Meropenem probably should be restricted to 3h infusions Berthoin K. J Antimicrob Chemother Feb 2010 Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
22 Possible advantages and disadvantages of continuous/long infusion vs bolus Administrations method Advantages Disadvantages Continuous / long infusion Predictable PK Requires education Lower daily dose may be effective Less time consuming for pharmacist / nurse Requires infusion pumps Issues of stability Bolus Simple Unpredictable PK Less likely failure / error Neurological side-effects probably more common Modified from Abdul-Aziz MH. Ann Intensive Care. 2012; 2: 37. Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
23 Doripenem / Ertapenem combination control ertapenem doripenem In vitro Doripenem + ertapenem In vivo Bulik CC. Antimicrob. Agents Chemother 2011;55(6):
24 Principles of PK/PD in ICU Carbapenems: prolonged/continuous or intermittent infusion? Colistin dosing Combination treatment Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
25 Target AUC/MIC: Colistin PK/PD Dudhani RV. Antimicrob Agents Chemother. 2010;54:
26 Colistin PK in critically ill patients 18 patients Cmax 0.6 mg/l after first dose Cmax 2.3 mg/l at steady state Plachouras D et al. Antimicrob Agents Chemother Aug;53(8):3430-6
27 CMS Concentration (mg/l) Dosage regimen simulation 3 MU x 3 9 MU MU x 2 12 MU MU x 2 9 MU (2h infusion) MU x 2 12 MU (2h infusion) MU x Time after first dose (hours) Colistin Concentration (mg/l) MU x 3 9 MU MU x 2 12 MU MU x 2 9 MU (2h infusion) MU x 2 12 MU (2h infusion) MU x Time after first dose (hours) Plachouras D et al. Antimicrob Agents Chemother Aug;53(8):3430-6
28 Concentration (µm) Plachouras et al., 2009 New data: PK of CMS and Colistin after 9MU 3MUq8h 0.25h inf Mohamed et al., MU Load, 3M 0.25h inf Karaiskos et al., unpublished data 9MU Load, h inf 9MU Load, 4.5 1h inf Time after dose (h) Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens 1st Dose 4th - 8th D Compound CMS Colistin Courtesy of Lena Friberg (Personal Communication)
29 Colistin pharmacodynamics Modelling of bacterial killing by various dosing regimens Mohamed AF.Antimicrob. Agents Chemother 2012;56(8):
30 Population PK in 105 critically ill patients Garnonzik SM. Antimicrob Agents Chemother 2010;54(3):
31 Colistin dosage individualisation Patient group All patients Not on renal replacement On hemodialysis On continuous hemofiltration *Ideal or actual body weight in kg (whichever is lower) Daily dose over 10mIU with caution Dose (miu CMS) for concentration target 2 mg/l Loading dose BW * /7.5 (max 10) Maintenance dose (Cl Cr /10)+2 in 2-3 doses 1 st dose 24 h after loading dose 2 (in two doses) +30% of the dose on the day of dialysis after the session 12 In two or three doses Garonzik SM et al. AAC 2011 (modified)
32 Colistin pharmacokinetics in patients on continuous venovenous hemodiafiltration (CVVHDF) Serum CMS (A) and colistin (B) concentrations CMS (A) and colistin (B) concentration before and after filter 5 patients 2 miu tid iv Cmax : 0.92 mg/l Extraction: 68% Karvanen M. Antimicrob. Agents Chemother 2013;57(1):
33 Is colistin effective? Prospective cohort study 495 patients Israel OR 1.99 bacteremic patients Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
34 Concentration dependent Bactericidal But Emergence of resistance Heteroresistance Adaptive resistance
35 Closing the Loop A Colistin Clinical Study to Confirm Dosing Recommendations From PK/PD Modeling Prospective study in 16 bed ICU 28 patients with infections by Colistin only susceptible (COS) Gramneg 14 patients on monotherapy Clinical cure: 23/28 patients (82.1%) Renal toxicity: 5/28 (17.8%) No emergence of colistin resistance under treatment Limitations: Uncontrolled study with few patients Dalfino L. Clin Infect Dis Jun;54(12): Roberts JA, Lipman J. Clin Infect Dis Jun;54(12): Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
36 Principles of PK/PD in ICU Carbapenems: prolonged/continuous or intermittent infusion? Colistin dosing Combination treatment Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
37 Colistin Carbapenem combination against carbapenemase producing enterobacteriaceae Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
38 Colistin Doripenem combination is synergistic and bactericidal against carbapenemase-producing colistin-resistant KP Backbone agent Colistin Doripenem Agent tested in combination Synergy, n (%) Indifference, n (%) Doripenem 6 (50) 6 (50) 0 Gentamicin 3 (25) 8 (67) 1 (8) Doxycycline 1 (8) 8 (67) 3 (25) Gentamicin 1 (8) 9 (75) 2 (17) Doxycycline 3 (25) 7 (58) 2 (17) Gentamicin Doxycycline 5 (42) 5 (42) 2 (17) Antagonism, n (%) Jernigan MG. Antimicrob. Agents Chemother 2012 ; 56(6):
39 Mortality according to treatment regimen in 67 patients with bloodstream infections with carbapenenemase producing KP Mortality % two active drugs one active drug inappropriate treatment Daikos Gl. Antimicrob Agents Chemother 2009;53:
40 Multicenter, open-label, randomized clinical trial to compare colistin alone vs. colistin plus carbapenem for severe infections caused by carbapenem-resistant bacteria. Preserving old antibiotics for the future Assessment of clinical efficacy by a pharmacokinetic/ pharmacodynamic approach to optimize effectiveness and reduce resistance for off-patent antibiotics
41 Conclusions Prolonged infusion of carbapenems may be more effective for the treatment of infections by multidrug resistant gram negative bacteria in critically ill patients Loading dose for colistin improves efficacy A combination of colistin and carbapenem may be of benefit in difficult to treat infections in critically ill patients Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course.31 May - 01 June 2013, Athens
42 Lena Friberg Otto Cars Matti Karvanen Ami Fazlin Mohamed Salim Bouchene David Khan Elisabet Nielsen Britt Jansson Swedish Foundation of Strategic Research Acknowledgements Ilias Karaiskos Helen Giamarellou K Pontikis E Papadomichelakis A Antoniadou A Armaganidis I Tsangaris G Poulakou F Kontopidou
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationPharmacokinetic-Pharmacodynamic (PKPD) Modeling Characterizing Resistance for Predictions of Bacterial Kill in vivo
Pharmacokinetic-Pharmacodynamic (PKPD) Modeling Characterizing Resistance for Predictions of Bacterial Kill in vivo Anders Kristoffersson Pascale David- Pierson, Neil John Parrott, Olaf Kuhlmann, Thierry
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationLa farmacologia in aiuto
Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams
More informationTherapy of MDR/XDR Gram-negative bacteria: dealing with the devil. CRE: high dosing, how much? by author
Therapy of MDR/XDR Gram-negative bacteria: dealing with the devil CRE: high dosing, how much? George L. Daikos, MD National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece
More informationTerapia delle infezioni da Pseudomonas aeruginosa MDR
Verona 23 ottobre 2010 Terapia delle infezioni da Pseudomonas aeruginosa MDR Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Global resistance surveillance of Pseudomonas aeruginosa
More informationLessons from recent studies. João Gonçalves Pereira UCIP DALI
Lessons from recent studies João Gonçalves Pereira UCIP DALI 1 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin
More information%T MIC MIC. Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration time-killing-curve 1990.
THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 159( 55 ) ( 2 15 ) %T MIC MIC 2002 30%T MIC 50%T MIC 1000 mg 3 3 /day Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationIs the package insert correct? PK considerations
Is the package insert correct? PK considerations Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,
More informationUse of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles
with the support of Wallonie-Bruxelles International Use of imipenem Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles 1 Β-lactams classification 2 Β-lactams: mode of action Inhibition
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationTherapeutic drug monitoring of β-lactams
CORATA Belgique Reims 1-2/10/2014 Therapeutic drug monitoring of β-lactams Frédéric Cotton Clinical Chemistry Erasme Hospital Faculty of Pharmacy ULB TDM of β-lactams β-lactams pharmacokinetics pharmacodynamics
More informationR EVIEWS O F T HERAPEUTICS
R EVIEWS O F T HERAPEUTICS Colistin: Understanding and Applying Recent Pharmacokinetic Advances Jessica K. Ortwine, 1 Keith S. Kaye, 2,3 Jian Li, 4 and Jason M. Pogue 3,5 * 1 Department of Pharmacy Services,
More informationDisclosures. Efficacy of the drug. Optimizing Dosing Based on PKPD- An overview. Dose Finding - The Past
Disclosures Optimizing Dosing Based on PKPD- An overview Johan W. Mouton MD PhD FIDSA FAAM Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker This Patient Needs Antibiotics.
More informationReporting blood culture results to clinicians: MIC, resistance mechanisms, both?
Reporting blood culture results to clinicians: MIC, resistance mechanisms, both? Christian G. Giske, MD, PhD Senior Consultant Physician/Associate Professor Department of Clinical Microbiology Karolinska
More informationLa batteriocidia sierica: passato e presente
Genova, 23 settembre 2016 La batteriocidia sierica: passato e presente Dott.ssa Maddalena Giannella Clinica di Malattie Infettive AOU Policlinico Sant Orsola Malpighi Case 1 Case 2 Summary: Cured of cancer
More informationContinuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients
Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients Jan O Friedrich, MD DPhil Associate Professor of Medicine, University of Toronto Medical Director, MSICU St. Michael s Hospital,
More informationSerum and Cerebrospinal Fluid Levels of Colistin. in Pediatric Patients
AAC Accepts, published online ahead of print on 28 June 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.01799-09 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationPharmacokinetics pharmacodynamics issues relevant for the clinical use of betalactam antibiotics in critically ill patients
Veiga and Paiva Critical Care (2018) 22:233 https://doi.org/10.1186/s13054-018-2155-1 REVIEW Pharmacokinetics pharmacodynamics issues relevant for the clinical use of betalactam antibiotics in critically
More informationPopulation pharmacokinetics of colistin methanesulphonate (CMS) and colistin in
AAC Accepted Manuscript Posted Online 4 January 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01868-15 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 Population pharmacokinetics
More informationby author ESCMID Online Lecture Library
The Karyatides at the Erechtheion Temple Devoted to the Women in the Audience At the top of the Museum the Karyatides, watching you through the years to come FOSFOMYCIN IN THE TREATMENT OF INFECTIONS
More informationZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN
ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN Anne Smits Fellow neonatologie UZ Leuven Use of antibiotics in neonates 50 European hospitals 23 non-european hospitals Countries n = 14 n = 9 Pediatric
More informationBasic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics
Basic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics This patient needs antibiotics. But which ones? Intensive care patient Ceftazidime,
More informationSBUH Aminoglycoside Dosing Protocol
Adult Aminoglycoside Dosing for Gram negative infections prior to available serum levels (Excludes patients with cystic fibrosis, OB GYN patients and surgical prophylaxis) Cr Cl 40 ml/min 5 7 mg/kg INT
More informationPharmacodynamic indices in targeting therapy of critical infections
Pharmacodynamic indices in targeting therapy of critical infections P.M. Tulkens Cellular and Molecular Pharmacology, Catholic University of Louvain, Brussels, Belgium & International Society of Anti-infective
More informationShould we be performing TDM in seriously ill patients with Gram negative infections?
Should we be performing TDM in seriously ill patients with Gram negative infections? Jason A Roberts B Pharm (Hons), PhD, FSHP Royal Brisbane and Women s Hospital, Australia. The University of Queensland,
More informationwithout the permission of the author Not to be copied and distributed to others
Emperor s Castle interior-prato What is the Role of Inhaled Polymyxins for Treatment of Respiratory Tract Infections? Helen Giamarellou CONCLUSIONS: Patients with Pseudomonas and Acinetobacter VAP may
More informationCRRT and Drug dosing. Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017
CRRT and Drug dosing Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017 This talk In scope CRRT modalities with regard to medicine Principles of drugs with regard to dialysis
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationPharmacodynamics: the methods
Pharmacodynamics: the methods In vitro models Animal models Clinical studies Population studies With the support of Wallonie-Bruxelles-International 3B-1 Pharmacodynamics: the methods "un peu de tout "
More informationWhy we need inhaled antibiotics?
Athens 19-20 November 2015 Why we need inhaled antibiotics? Garyfallia Poulakou Consultant, Infectious Diseases 4 th Dept of Internal Medicine, Attikon University Hospital of Athens TRANSPARENCY DECLARATION
More informationNightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017
Nightmare Bacteria How to Deal with the Reality of Carbapenem-resistant Organisms Disclosures I have no conflicts of interest relative to the content of this presentation Matthew L. Brown, Pharm.D., BCPS
More informationAcademic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE
Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationprophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures
1 Glycopeptides appropriate uses serious infections due to beta-lactam- resistant gram-positive microorganisms infections due to gram-positive microorganisms in patients with serious allergy to beta-lactam
More informationANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO
ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland NO CONFLICT OF INTERESTS Important concept
More informationDoripenem: pharmacokinetics and pharmacodynamics. Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD
16/04/2009 1 Doripenem: pharmacokinetics and pharmacodynamics Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD Unité de Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute
More informationTreatment Strategies for Infections due to MDR-GNR
Treatment Strategies for Infections due to MDR-GNR Michael Satlin, MD Instructor in Medicine Division of Infectious Diseases Weill Cornell Medical College, New York, NY October 16, 2012 1 2 Faculty Disclosure
More informationAntibiotic Usage Related to Microorganisms Pattern and MIC
Antibiotic Usage Related to Microorganisms Pattern and MIC DR. Dr. Latre Buntaran Sp.MK(K) Secretary General PERDALIN Head of Compartment of Infection Control PERSI Doripenem: Potent
More informationDiane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center
Diane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center The information disseminated in this lecture is given in my personal
More informationCURRENT GUIDELINES FOR SEPSIS MANAGEMENT
HELLENIC SEPSIS STUDY GROUP www.sepsis.gr CURRENT GUIDELINES FOR SEPSIS MANAGEMENT Evangelos J. Giamarellos-Bourboulis, MD, PhD Associate Professor of Medicine 4 th Department of Internal Medicine, National
More informationTowards clinical Applications of PK-PD in specific situations
Towards clinical Applications of PK-PD in specific situations P.M. Tulkens Cellular and Molecular Pharmacology & Center for Clinical Pharmacy, Catholic University of Louvain, Brussels, Belgium with many
More informationUse of Colistin. Dr. Maya Hites Dept. of Infectious Diseases CUB-Erasme, Université Libre de Bruxelles NVMM/VIZ/BVIKM/SBIMC Fall Meeting 17/11/2017
Use of Colistin Dr. Maya Hites Dept. of Infectious Diseases CUB-Erasme, Université Libre de Bruxelles NVMM/VIZ/BVIKM/SBIMC Fall Meeting 17/11/2017 Disclosure (potential) conflict of interest For this meeting
More informationStanford Health Care Last Review Date: 8/2016 Pharmacy Department Policies and Procedures
Medication Administration: Extended-Infusion Piperacillin/Tazobactam (Zosyn ) Protocol Related Documents: Patient Care Manual Guide: Medication Administration IV Infusion Guidelines I. PURPOSE Dose optimization
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationSCMID Online Lecture Library. by author. Optimizing antimicrobial therapy in the elderly. Dose Finding - The Past
Optimizing antimicrobial therapy in the elderly Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Dosing should be such that the level of antmicrobial activity is associated
More informationESCMID Online Lecture Library. by author
www.eucast.org EXPERT RULES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad
More informationPK/PD degli antibiotici utilizzati nella sepsi
PK/PD degli antibiotici utilizzati nella sepsi Dario Cattaneo, U.O. Farmacologia Clinica ASST Fatebenefratelli Sacco, Milano Bergamo, città alta Variability of antibiotic concentrations in critically ill
More informationMRSA Micro Scan Pos Combo 6J DADE BEHRING VCM
PKPD MRSA 1 1 2 1 1 2 17 1 26 17 3 16 vancomycinvcm methicillin-resistant Staphylococcus aureusmrsa 31 pharmacokineticpkparameter retrospective VCM 21 10 PK parameter Mann- Whitney U-test Cmax 37.1 µ gml29.942
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationDrug Management in CRRT
Drug Management in CRRT Jeffrey Lipman, FCICM, MD Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland Bruce A. Mueller, PharmD, FCCP, FASN Clinical, Social & Administrative
More informationOptimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches
Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator
More informationAminoglycosides John A. Bosso, Pharm.D.
AMINOGLYCOSIDES Therapeutics/PHRMP-73 Aminoglycoside Mechanism of Action Aminoglycosides bind to 30s ribosomal subunit resulting in mistranslation of mrna thus disrupting protein synthesis. They are rapidly
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationIntracheal antibiotics administration
Intracheal antibiotics administration Jean Chastre, M.D. www.reamedpitie.com Disclosure Conflicts of interest: Consulting or Lecture fees: Bayer, Pfizer, Cubist/Merck, Basilea, Kenta/Aridis, Roche, AstraZeneca/Medimmune
More informationPresented at the annual meeting of the American Society of Microbiology, June 1-5, 2017, New Orleans, LA, USA
Is Associated With Improved Survival and Safety Compared to Colistin in Serious Carbapenemresistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study Lynn E. Connolly 1, Adrian M. Jubb 1,
More informationReceived 22 July 2018; returned 14 August 2018; revised 5 November 2018; accepted 13 November 2018
J Antimicrob Chemother doi:1.193/jac/dky511 Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent
More informationProfessor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence
Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence Researching field Pharmacokinetics, Pharmacodynamics of antimicrobial, antifungal and antitumoral drugs
More informationVANCOMYCIN DOSING AND MONITORING GUIDELINES
VANCOMYCIN DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee Approved: May 2017 GENERAL COMMENTS Vancomycin is a glycopeptide antibiotic with bactericidal
More informationOptimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria
Infect Dis Ther (2015) 4:391 415 DOI 10.1007/s40121-015-0093-7 REVIEW Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria Phillip J. Bergen Zackery P. Bulman Cornelia B. Landersdorfer
More informationChallenges in Therapeutic Drug Monitoring:
Challenges in Therapeutic Drug Monitoring: Focus on Vancomycin Pharmacodynamics and Pharmacokinetics Katherine Gallaga, PharmD PGY1 Pharmacy Practice Resident CHRISTUS Spohn Health System 1 Pharmacist
More informationOptimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology
ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»
More informationConsequences for the clinicians
30th Symposium : What will change in your daily practice with the new Elewijt, 26-05-2008 EUCAST breakpoints for antibiotic susceptibility testing Consequences for the clinicians Y.Van Laethem,MD CHU St
More informationPharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis
AAC Accepts, published online ahead of print on 1 April 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00230-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Pharmacokinetics
More informationReceived 13 December 2010/Returned for modification 13 March 2011/Accepted 28 April 2011
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2011, p. 3284 3294 Vol. 55, No. 7 0066-4804/11/$12.00 doi:10.1128/aac.01733-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Population
More informationDrug-resistant Infections
Treatment Options for Infections Caused by Carbapenem-resistant Gram-negative Bacteria Chris Kosmidis, 1 Garyphalia Poulakou, 2 Antonios Markogiannakis 3 and George L Daikos 4 1. Research Associate, First
More informationTreatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
REVIEW ARTICLE Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections Haley J. Morrill, 1,2 Jason M. Pogue, 3 Keith S. Kaye, 4 and Kerry L. LaPlante 1,2,5 1 Veterans Affairs Medical Center,
More informationPHARMACOKINETICS OF COLISTIN IN
PHARMACOKINETICS OF COLISTIN IN CRITICALLY ILL PATIENTS WITH MULTIDRUG-RESISTANT GRAM- NEGATIVE BACILLI INFECTION JOURNAL CLUB PRESENTATION Amal M. Al-Anizi, PharmD Candidate KSU, Infectious disease rotation
More informationESCMID Online Lecture Library. by author
Disclosures Pk/Pd of antifungal drugs Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker Dosing should be such that the level of antmicrobial
More informationAchieving pharmacokinetic/pharmacodynamic (PK/PD) targets of β-lactams in critically ill patients at first dose: Can we do it with standard dosing?
Oral session: PK/PD-based optimized broad-spectrum beta-lactam therapy (Sunday 10 April, 11:30) Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets of β-lactams in critically ill patients at first
More informationWhat is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden
What is new in EUCAST 2016 17 South Africa, May, 2016 Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden What is new in EUCAST 2016/17? New organisms with breakpoints (Addendum 2016)
More informationMDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES
MDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES 1 Marin H. Kollef, MD Professor of Medicine Virginia E. and Sam J. Golman Chair in Respiratory Intensive Care Medicine Washington University School of
More informationOutcomes with ceftazidime/avibactam in patients with carbapenem-resistant Enterobacteriaceae (CRE)
AAC Accepted Manuscript Posted Online 8 May 2017 Antimicrob. Agents Chemother. doi:10.1128/aac.00449-17 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 3 Outcomes with ceftazidime/avibactam
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationEvaluation of Vancomycin Continuous Infusion in Trauma Patients
OBJECTIVES Evaluation of Vancomycin Continuous Infusion in Trauma Patients Brittany D. Bissell, Pharm.D. PGY-2 Critical Care Pharmacy Resident Jackson Memorial Hospital Miami, Florida Evaluate the potential
More informationJournal of Pediatric Sciences
Journal of Pediatric Sciences Doripenem Use in Pediatrics - Learning from Pharmacokinetic Data of Other Carbapenems Patrick Grove, Tsz-Yin So Journal of Pediatric Sciences; How to cite this article: Grove
More informationCLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel
CLINICAL USE OF GLYCOPEPTIDES Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel Glycopeptides Natural Vancomycin introduced in 1958 Teicoplanin introduced in Europe
More informationβ- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication
Prevalence of Carbapenem-Hydrolyzing β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication David Alcid M.D Balaji Yegneswaran M.D. Wanpen Numsuwan Introduction Klebsiella pneumoniae
More informationMedication Dosing in CRRT
Medication Dosing in CRRT Linda Awdishu, PharmD, MAS Associate Clinical Professor of Pharmacy and Medicine Learning Objectives 1. List the pharmacokinetic changes associated with AKI. 2. Determine the
More informationPHA5128 Dose Optimization II Case Study 3 Spring 2013
Use the vancomycin dosing nomogram table below: A female patient, 57 years of age, 5 6 in height and 100 in weight had an infection requiring vancomycin treatment. Her serum creatinine was 0.8 mg/d. What
More informationLimiting the Attributable Mortality of. Healthcare-Associated Infection & Multidrug Resistance. in Critically Ill Patients
Sigma Theta Tau International 26 th International Nursing Research Congress San Juan, Puerto Rico, 23-27 July 2015 Limiting the Attributable Mortality of Healthcare-Associated Infection & Multidrug Resistance
More informationColistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients
Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients Matthew E. Falagas, Petros I. Rafailidis, Elda Ioannidou,
More informationPenetration of colistin into the cerebrospinal fluid
AAC Accepts, published online ahead of print on August 00 Antimicrob. Agents Chemother. doi:./aac.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Pharmacy Faculty, Siam University, Bangkok, Thailand
1 2 Article Type: Guest Ed Mistakes We Make in Dialysis 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 We underdose antibiotics in patients on CRRT Alexander R. Shaw Weerachai Chaijamorn Bruce A. Mueller 1 Ann
More informationβ-lactamase inhibitors
β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine
More informationDosing Guidance for Intravenous Colistin in Critically Ill Patients
Clinical Infectious Diseases MAJOR ARTICLE Dosing Guidance for Intravenous Colistin in Critically Ill Patients Roger L. Nation, 1 Samira M. Garonzik, 3 Visanu Thamlikitkul, 5 Evangelos J. Giamarellos-Bourboulis,
More informationESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationNadira Durakovic, Vedran Radojcic, Ana Boban, Mirando Mrsic, Dubravka Sertic, Ranka Serventi-Seiwerth, Damir Nemet and Boris Labar.
ORIGINAL ARTICLE Efficacy and Safety of Colistin in the Treatment of Infections Caused by Multidrug-resistant Pseudomonas aeruginosa in Patients with Hematologic Malignancy: A Matched Pair Analysis Nadira
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationExtrapolation in antibacterial agents
Extrapolation in antibacterial agents Irja Lutsar University of Tartu, Estonia Maria Fernandez Cortizo- Medicines Agency, Spain EMA meeting, 30.09.2015 Glossary PIP: Paediatric Investigation Plan AHOM:
More informationContinuous Renal Replacement Therapy. Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD 1 Definition of Terms SCUF - Slow Continuous Ultrafiltration
More informationIn vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant Pseudomonas aeruginosa
Antimicrobial Section / Original Paper Received: April 12, 2016 Accepted: August 23, 2016 Published online: October 28, 2016 In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in
More informationGuess or get it right?
Guess or get it right? Antimicrobial prescribing in the 21 st century Robert Masterton Traditional Treatment Paradigm Conservative start with workhorse antibiotics Reserve more potent drugs for non-responders
More information